Hyperthermic isolated limb perfusion for XXXX : response and survival.

@entity1 @entity9855 @entity583 @entity204 @entity320
Response to and survival after hyperthermic isolated limb perfusion (HILP) with melphalan in @entity1 with @entity320 at the Royal Brisbane Hospital were reviewed in order to assess the major determinants of response to treatment. Data were collected by clinical chart review and direct @entity1 contact. Response was assessed by clinical observation and measurement of nodules. Survival was calculated from the date of perfusion to the date of @entity1 @entity204 . Since 1965 there have been 85 @entity1 (38 @entity1 , 47 @entity1 ) who have undergone 109 limb (102 leg, 7 arm) perfusions. The mean age was 58 years (range 32-82 years). The number of @entity1 per disease stage (M.D. Anderson classification) was as follows: stage I, 5 @entity1 ; stage II, 8 @entity1 ; stage IIIa, 41 @entity1 ; stage IIIab, 25 @entity1 ; and stage IIIb, 8 @entity1 . The mean duration of perfusion was 81 minutes. Melphalan was given in divided doses, with a mean total dose 1.39 mg/kg. The mean maximal limb temperature was 41.5 degrees @entity9855 complications occurred during 20 perfusions (18%). There was one postoperative @entity204 from @entity583 , and one @entity1 required amputation. Median @entity1 follow-up was 2.65 years (range 1-27 years). A complete response was noted in 34 @entity1 (40%), a partial response in 36 @entity1 (42%), and no response in 11 @entity1 (13%). Response could not be assessed in four @entity1 . The actuarial 5-year survival for the whole group was 45%: stage I, 80%; stage II, 75%; stage IIIa, 44%; stage IIIab, 23%; stage IIIb, 56%. The two significant determinants of response to perfusion were disease stage (p = 0.00005) and nodal status (p = 0.03).(ABSTRACT TRUNCATED AT 250 WORDS)
